https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-26 / J Immunol Res 2018;2018:8740976
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-26 / J Immunol Res 2018;2018:87409762018-03-26 00:00:002018-03-26 00:00:00Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-21 / Semin. Cell Dev. Biol. 2019 Feb;86:77-88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-21 / Semin. Cell Dev. Biol. 2019 Feb;86:77-882018-03-21 00:00:002019-03-25 10:43:23Dendritic cells as cancer therapeutics
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-18 / J Immunol Res 2018;2018:3982942
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-18 / J Immunol Res 2018;2018:39829422018-03-18 00:00:002019-02-15 08:49:53Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-06 / J Immunother Cancer 2018 Mar;6(1):19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-06 / J Immunother Cancer 2018 Mar;6(1):192018-03-06 00:00:002019-02-15 08:49:55Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-01 / Front Immunol 2018;9:394
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-01 / Front Immunol 2018;9:3942018-03-01 00:00:002019-02-15 08:36:03Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-21 / Hum Vaccin Immunother 2018 Jun;14(6):1423-1431
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-21 / Hum Vaccin Immunother 2018 Jun;14(6):1423-14312018-02-21 00:00:002018-02-21 00:00:00Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-15 / Blood Rev. 2018 Jul;32(4):312-325
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-15 / Blood Rev. 2018 Jul;32(4):312-3252018-02-15 00:00:002019-02-15 08:32:43Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-08 / J Clin Oncol 36, 2018 (suppl 6S; abstr 219)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-08 / J Clin Oncol 36, 2018 (suppl 6S; abstr 219)2018-02-08 00:00:002018-02-08 00:00:00Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-08 / JCI Insight 2018 Feb;3(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-08 / JCI Insight 2018 Feb;3(3)2018-02-08 00:00:002019-02-15 08:32:51Efficacy of intracellular immune checkpoint-silenced DC vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-08 / Int. J. Biol. Macromol. 2018 Jul;113:1182-1187
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-08 / Int. J. Biol. Macromol. 2018 Jul;113:1182-11872018-02-08 00:00:002019-02-15 08:35:40Poly(I:C) enhanced anti-cervical cancer immunities induced by dendritic cells-derived exosomes
